Remove the-link-between-patient-engagement-and-reimbursement
article thumbnail

Payor-Led Initiatives to Strengthen Mental Health Resources

Healthcare Law Blog

For example, an overwhelming sixty percent (60%) of recently-surveyed licensed psychologists reported having no openings for new patients, with many having a volume of patient requests that outweighs their ability to even maintain a waitlist. [1]

article thumbnail

Home Health PPS Final Rule for CY 2024: CMS Steps Back from the Brink

Hall Render

The 2024 Final Rule was the subject of a significant amount of advocacy by the industry due to CMS’s proposed significant rate cut to offset behavioral changes under the Patient-Driven Groupings Model (“PDGM”). CMS stated that this rate cut was necessary to meet the budget neutrality requirements under PDGM. or $140 million in 2024.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Day 1 Notes from the 41st Annual J.P. Morgan Healthcare Conference

Healthcare Law Blog

The way we have allowed the healthcare system in the United States to operate means that very few people have a single integrated and coordinated healthcare solution for their needs and that often no one is fully responsible for a patient’s care and financial coordination. I was struck on the first day of the 41 st Annual J.P.

article thumbnail

The Health Consumer in 2024 – The Health Populi TrendCast

Jane Sarashon

At the end of each year since I launched the Health Populi blog, I have put my best forecasting hat on to focus on the next year in health and health care. For this round, I’m firmly focused on the key noun in health care, which is the patient – as consumer, as Chief Health Officer of the family, as caregiver, as health citizen.

article thumbnail

FDA and Off-Label Communication – Getting Closer to Truth

Drug & Device Law

In addition to its recent revamp of its “§510(k)” substantial equivalence clearance process for medical devices, (see our post here ), the FDA has also been active with respect to off-label communications – another regulatory area of continuing interest to this Blog. E.g. , Sorrell v. Caronia , 703 F.3d 3d 149 (2d Cir. FDA , 119 F.

FDA 64